{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-063036","form_type":"8-K","ticker":"HEPA","cik":"0001583771","company_name":"Hepion Pharmaceuticals, Inc.","filed_at":"2023-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.515635+00:00","generated_at":"2026-06-14T18:13:56.326474+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Hepion Phase 2 ALTITUDE-NASH trial meets primary endpoint with rencofilstat 225 mg improving liver function","bullets":["Phase 2 trial met primary endpoint: 225 mg rencofilstat reduced DSI by 1.62 units (p<0.05) and SHUNT by 2.8% (p<0.05).","61% of 225 mg arm achieved ≥2-point DSI improvement (p<0.05); RISK ACE reduced 1.2 events/100 pt-yrs (p<0.001).","Secondary endpoints: ALT ↓21.6%, AST ↓4.7%, ProC3 ↓9.6%, PIIINP ↓5.6%, ELF score ↓2.5% at 225 mg (all p<0.001).","Rencofilstat well tolerated; no drug-related SAEs; supports ongoing Phase 2b ASCEND-NASH paired biopsy trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-063036","json":"https://secwatch.observer/filing/0001104659-23-063036.json","markdown":"https://secwatch.observer/filing/0001104659-23-063036.md","text":"https://secwatch.observer/filing/0001104659-23-063036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583771/000110465923063036/0001104659-23-063036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583771/000110465923063036/tm2316423d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T18:13:56.326474+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}